A high–molecular-weight methacrylate-based dendronized polyglycerol sulfate polymer exhibits exceptional binding and inhibition of SARS-CoV-2 (IC₅₀ ≈ 0.3 µg/mL) and other viruses. Its polyvalent electrostatic interactions and steric shielding outperform existing polymeric inhibitors. A biodegradable, mucus-mimetic hydrogel formulation enables nasal spray delivery.

Detailed Explanation

This invention defines a polymer featuring dendronized polyglycerol backbones functionalized with sulfate (or carboxylate) groups. As single-chain fibers (~150–215 nm), the polymers engage viral spike proteins via multivalent electrostatics. In vitro assays demonstrate lower IC₅₀ than linear polyglycerol sulfate (LPGS)  and heparin. Hydrogel networks form via UV or thiol-disulfide crosslinking with PEG derivatives, yielding tunable rheology akin to native mucus. Hydrogels degrade under physiological glutathione concentrations, ensuring clearance. Low anticoagulant activity and high cell viability support safe therapeutic use. Scalable RAFT polymerization routes enable gram-scale production.

Key Innovation Features and Advantages

• Single-chain polymer fibers that maximize surface contact with viral particle
• Ultra-low IC₅₀ values against SARS-CoV-2, HSV-1, and RSV
• Dual mechanism: polyvalent binding and steric shielding of viral spike protein
• Mucus-like rheological properties in hydrogel form for respiratory applications
• Biodegradable via glutathione-triggered disassembly
• Minimal anticoagulant activity for improved safety
• Scalable synthesis using bifunctional chain transfer agents

 Use Cases

• Prophylactic nasal sprays to block viral entry at the nasal mucus
• Topical antivirals for skin or mucosal infections
• Biocompatible hydrogels for respiratory tract coatings
• Lubricants with embedded antimicrobial protection
• In vitro 3D cell and organoid cultures with antiviral matrices

Commercial Opportunities

• Over-the-counter antiviral nasal formulations for pandemic response
• Licensing hydrogel technology for pharmaceutical companies
• Medical devices: infection-resistant wound dressings and implants
• Cell therapy scaffolds for stem cell expansion and delivery
• Platform polymer for next-gen antiviral and antibacterial therapeutics

Current Status

Core polymer synthesis and scale-up validated. Viral inhibition confirmed across multiple pathogens and cell lines. Hydrogel prototypes characterized for rheology, degradability, and virus binding. Ready for formulation development and preclinical evaluation.